✦ Reinvesting $3 Billion of SavingsThin moat

Merck & Co. (MRK) — the future bets

Merck is cutting $3 billion a year of costs by 2027 and says every dollar will go back into growth.

Merck's least glamorous bet is on itself. Its 2025 restructuring programme is expected to cost about $3.0 billion and to produce annual savings of about $1.7 billion, substantially realised by the end of 20271. It is part of a multiyear initiative expected to achieve $3.0 billion of annual savings by the end of 2027, "which will be fully reinvested into strategic growth areas of the business"2.

Selling, general and administrative expenses ($M)10,504202310,816202410,7332025Merck Form 10-K FY2025, income statement
Flat while sales grew.

Restructuring costs showed the programme starting: $889 million in 2025 against $309 million in 20243. Merck had about 75,000 employees at the end of 20254.

The point is to fund launches without raising total spending. Selling, general and administrative expenses were $10,733 million in 2025 against $10,816 million in 20245, roughly flat while sales grew, and the savings are meant to keep it that way while the new products are promoted.

The risk is that the savings are absorbed by the Keytruda decline rather than invested. A company that cuts costs to protect margins is defending; one that cuts to fund growth is attacking. Merck says it is doing the second.

The workforce is large and stable. About 73,000 of Merck's employees are full-time, about 21% are covered by collective bargaining agreements and voluntary turnover was about 4.8% in 20256. Savings of this size will come partly from people, and partly from the manufacturing network the programme is also restructuring.

This bet is modest and measurable. Restructuring costs, $889 million in 20257, are the figure to follow into 2027; if they keep rising while selling expenses fall rather than hold steady, the programme will have become a margin defence rather than a reinvestment.

Moat trajectory: Holding steady

Restructuring costs $889M in 2025; savings targeted by end-2027.

The number that tests this moat
Reported
Restructuring costs, full year
$889M (2025), against $309M in 2024

The cost of the savings programme; rising costs with falling selling expenses would mean defence, not reinvestment.

Source: Merck Form 10-K, FY2025 ↗
References
  1. ReportedIts 2025 restructuring programme is expected to cost about $3.0 billion and to produce annual savings of about $1.7 billion, substantially realised by the end of 2027.
    Merck & Co. Form 10-K for fiscal 2025 - financial statements and notes: earnings, cash flow, balance sheet, acquisitions, research and segment profit. — FY2025 · publ. 24 February 2026 · source ↗
  2. ReportedIt is part of a multiyear initiative expected to achieve $3.0 billion of annual savings by the end of 2027, "which will be fully reinvested into strategic growth areas of the business".
    Merck & Co. Form 10-K for fiscal 2025 - financial statements and notes: earnings, cash flow, balance sheet, acquisitions, research and segment profit. — FY2025 · publ. 24 February 2026 · source ↗
  3. ReportedRestructuring costs showed the programme starting: $889 million in 2025 against $309 million in 2024.
    Merck & Co. Form 10-K for fiscal 2025 - financial statements and notes: earnings, cash flow, balance sheet, acquisitions, research and segment profit. — FY2025 · publ. 24 February 2026 · source ↗
  4. ReportedMerck had about 75,000 employees at the end of 2025.
    Merck & Co. Form 10-K for fiscal 2025 - financial statements and notes: earnings, cash flow, balance sheet, acquisitions, research and segment profit. — FY2025 · publ. 24 February 2026 · source ↗
  5. ReportedSelling, general and administrative expenses were $10,733 million in 2025 against $10,816 million in 2024, roughly flat while sales grew, and the savings are meant to keep it that way while the new products are promoted.
    Merck & Co. Form 10-K for fiscal 2025 - financial statements and notes: earnings, cash flow, balance sheet, acquisitions, research and segment profit. — FY2025 · publ. 24 February 2026 · source ↗
  6. ReportedAbout 73,000 of Merck's employees are full-time, about 21% are covered by collective bargaining agreements and voluntary turnover was about 4.8% in 2025.
    Merck & Co. Form 10-K for fiscal 2025 - financial statements and notes: earnings, cash flow, balance sheet, acquisitions, research and segment profit. — FY2025 · publ. 24 February 2026 · source ↗
  7. ReportedRestructuring costs, $889 million in 2025, are the figure to follow into 2027; if they keep rising while selling expenses fall rather than hold steady, the programme will have become a margin defence rather than a reinvestment.
    Merck & Co. Form 10-K for fiscal 2025 - financial statements and notes: earnings, cash flow, balance sheet, acquisitions, research and segment profit. — FY2025 · publ. 24 February 2026 · source ↗
Sources
Generated September 25, 2026